Tirofiban in acute coronary syndromes

References

• Bertrand ME, Simoons ML, Fox KA et al; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J.23(23), 1809–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. J. Am. Coll. Cardiol.36, 970–1056 (2000).
   PubMed Web of Science ®Google Scholar
• Fox KA, Goodman SG, Klein W et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J.23(15), 1177–89 (2002).
   PubMed Web of Science ®Google Scholar
• Hasdai D, Behar S, Wallentin L et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur. Heart J.23(15), 1190–1201 (2002).
   PubMed Web of Science ®Google Scholar
• Shah PK. Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol.41(4 Suppl. S), S15–S22 (2003).
   Web of Science ®Google Scholar
• Cannon CP. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. J. Am. Coll. Cardiol.41(4 Suppl. S), S43–S48 (2003).
   Google Scholar
• Hynes RO. Integrins: a family of cell surface receptors. Cell48(4), 549–554 (1987).
   PubMed Web of Science ®Google Scholar
• Duperray A, Troesch A, Berthier R et al. Biosynthesis and assembly of platelet GP IIb-IIIa in human megakaryocytes: evidence that assembly between pro-GP IIb and GP IIIa is a prerequisite for expression of the complex on the cell surface. Blood74(5), 1603–1611 (1989).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Byzova TV, Plow EF. Platelet GP IIb-IIIa blockers. Lancet353(9148), 227–231 (1999).
   PubMed Web of Science ®Google Scholar
• Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med.332(23), 1553–1559 (1995).
   PubMed Web of Science ®Google Scholar
• Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation103(2), 201–206 (2001).
   PubMed Web of Science ®Google Scholar
• Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Drugs63(11), 1121–1163 (2003).
   PubMed Web of Science ®Google Scholar
• Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia and retreatment. Am. Heart J.139(2 Pt 2), S38–S45 (2000).
   PubMed Web of Science ®Google Scholar
• Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. Crit. Care Med.30(Suppl. 5), S332–S340 (2002).
   PubMed Web of Science ®Google Scholar
• Hermann HC. Tirofiban – an overview of the Phase III trials. J. Invasive Cardiol.11(Suppl. C) C7–C13 (1999).
   Google Scholar
• Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin. Pharmacokinet. 41(3), 187–195 (2002).
   PubMed Web of Science ®Google Scholar
• PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management. N. Engl. J. Med.338(21), 1498–1505 (1998).
   PubMed Web of Science ®Google Scholar
• PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N. Engl. J. Med.338(21), 1488–1497 (1998).
   PubMed Web of Science ®Google Scholar
• The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med.339(7), 436–443 (1998).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation106(14), 1893–1900 (2002).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N. Engl. J. Med.344(25), 1879–1887 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson HV, Cannon CP, Stone PH et al. 1-year results of the Thrombolysis In Myocardial Infarction (TIMI)-IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J. Am. Coll. Cardiol.26(7), 1643–1650 (1995).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Lagerqvist B, Husted S et al. Outcome at 1 year after an invasive compared with a noninvasive strategy in unstable coronary-artery disease: the FRISC II invasive randomized trial. FRISC II Investigators. Fast revascularization during instability in coronary artery disease. Lancet 356(9223), 9–16 (2000).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N. Engl. J. Med.341(5), 319–327 (1999).
   PubMed Web of Science ®Google Scholar
• Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. J. Am. Med. Assoc.284(7), 835–842 (2000).
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Kastrati A, Pogatsa-Murray G et al. Evaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. J. Am. Med. Assoc.290(12), 1593–1599 (2003).
   PubMed Web of Science ®Google Scholar
• van't Hof AW, de Vries ST, Dambrink JH et al. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes. Eur. Heart J.24(15), 1401–1405 (2003).
   PubMed Web of Science ®Google Scholar
• The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation96(5), 1445–1453 (1997).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Goel M, Cohen DJ et al. 6-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. J. Am. Coll. Cardiol.32(1), 28–34 (1998).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med.344(25), 1888–1894 (2001).
   PubMed Web of Science ®Google Scholar
• Stone GW, Moliterno DJ, Bertrand M et al. Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial. Circulation105(20), 2347–2354 (2002).
   PubMed Web of Science ®Google Scholar
• Moliterno DJ, Yakubov SJ, DiBattiste PM et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization with stent placement: the TARGET follow-up study. Lancet 360(9330), 355–360 (2002).
   PubMed Web of Science ®Google Scholar
• Kabbani SS, Aggarwal A, Terrien EF et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am. J. Cardiol.89(5), 647–650 (2002).
   PubMed Web of Science ®Google Scholar
• Batchelor WB, Tolleson TR, Huang Y et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro and Eptifibatide. Circulation106(12), 1470–1476 (2002).
   PubMed Web of Science ®Google Scholar
• Saucedo JF, Garza L, Wolford DC et al. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am. J. Cardiol.93(10), 1279–1282 (2004).
   PubMed Web of Science ®Google Scholar
• Bonz AW, Lengenfelder B, Strotmann J et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J. Am. Coll. Cardiol.40(4), 662–668 (2002).
   PubMed Web of Science ®Google Scholar
• Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am. J. Cardiol.89(5), 647–650 (2002).
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schomig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J. Am. Coll. Cardiol.37(5), 1323–1328 (2001).
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Herrmann HC, Lakkis N et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am. J. Cardiol.90(12), 1421–1423 (2002).
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Herrmann HC, Lakkis N et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am. J. Cardiol.91(3), 334–336 (2003).
   PubMed Web of Science ®Google Scholar
• Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc. Interv. 61, 179–184 (2004).
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Percoco G, Barbieri D et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J. Am. Coll. Cardiol.44(1), 14–19 (2004).
   PubMed Web of Science ®Google Scholar
• Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart J.140(2), 206–211 (2000).
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi ML, Menozzi A et al. Thrombocytopenia caused by abciximab or tirofiban, and its association with clinical outcome in patients undergoing coronary stenting. Circulation 109(18), 2203–2206 (2004).
   PubMed Web of Science ®Google Scholar
• Bougie DW, Wilker PR, Wuitschick ED et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GP IIb/IIIa. Blood100(6), 2071–2076 (2002).
   PubMed Web of Science ®Google Scholar
• Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur. Heart J.21(18), 1502–1513 (2000).
   PubMed Web of Science ®Google Scholar
• Theroux P, Ouimet H, McCans J et al. Aspirin, heparin or both to treat acute unstable angina. N. Engl. J. Med.319(17), 1105–1111 (1988).
   PubMed Web of Science ®Google Scholar
• The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336(8719), 827–830 (1990).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor inhibition in Ischemic Syndrome Management. Lancet 354(9192), 1757–1762 (1999).
   PubMed Web of Science ®Google Scholar
• Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation104(23), 2767–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Barr E, Snapinn SM, DiBattiste PM et al. GP IIb/IIIa receptor blockade improves outcomes in unstable angina/non-Q-wave myocardial infarction regardless of the treatment strategy employed during the initial hospitalization: analysis of outcomes in PRISM-PLUS. Am. J. Cardiol. (In press).
   Google Scholar
• Bizzarri F, Scolletta S, Tucci E et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg.122(6), 1181–1185 (2001).
   PubMed Web of Science ®Google Scholar
• Waters RE 2nd, Mahaffey KW, Granger CB, Roe MT. Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. Am. Heart J.146(6), 958–968 (2003).
   PubMed Web of Science ®Google Scholar
• Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 357(9272), 1905–1914 (2001).
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacyof a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 358(9282), 605–613 (2001).
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol.42(1), 1–6 (2003).
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. J. Am. Coll. Cardiol.44(3), E1–E211 (2004).
   PubMedGoogle Scholar
• Lee DP, Herity NA, Hiatt BL et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation107(11), 1497–1501 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez-Rios MA, Rosas M, Gonzalez H et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am. J. Cardiol.93(3), 280–287 (2004).
   PubMed Web of Science ®Google Scholar
• van't Hof AW, Ernst N, de Boer MJ et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ONgoing Tirofiban In Myocardial infarction Evaluation (ON-TIME) trial. Eur. Heart J.25(10), 837–846 (2004).
   PubMed Web of Science ®Google Scholar
• Danzi GB, Sesana M, Capuano C et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am. J. Cardiol.94(1), 35–39 (2004).
   PubMed Web of Science ®Google Scholar
• Cohen M. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update. Drugs62(12), 1755–1770 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. J. Invasive Cardiol. (12 Suppl. E), E5–E9 (2000).
   Google Scholar
• Cohen M, Theroux P, Borzak S et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am. Heart J.144(3), 470–477 (2002).
   PubMed Web of Science ®Google Scholar
• Ferguson JJ, Antman EM, Bates ER et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am. Heart J.146(4), 628–634 (2003).
   PubMed Web of Science ®Google Scholar
• Blazing MA, De Lemos JA, White HD et al. Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. J. Am. Med. Assoc. 292, 55–64 (2004).
   PubMed Web of Science ®Google Scholar
• Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. J. Am. Med. Assoc. 292(1), 45–54 (2004).
   PubMed Web of Science ®Google Scholar
• Peters RJ, Mehta SR, Fox KA et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation108(14), 1682–1687 (2003).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J. Am. Med. Assoc. 288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Chan AW, Moliterno DJ, Berger PB et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J. Am. Coll. Cardiol.42(7), 1188–1195 (2003).
   PubMed Web of Science ®Google Scholar